Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of limited fresh-freezing capacity on patients’ access to emerging cancer (a) testing and (b) treatments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of (a) fresh-freezing, (b) snap-freezing and (c) flash frozen capacity for brain cancer tissue samples across NHS trusts in England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the adequacy of the NHS’s capacity for fresh freezing of (a) tumour and (b) other tissue samples.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the recommendations on NHS culture in the Tessa Jowell Brain Cancer Mission's report entitled Closing the Gap, published in September 2024.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
As part of the National Cancer Plan, we have engaged with brain cancer clinical experts and charities, as well as receiving this report, to help us develop the plan. The plan will include how we can reform the workforce to improve cancer patient outcomes, including for patients with brain cancer.
On 24 October 2025, NHS England published the Medium-Term Planning Framework – delivering change together 2026/27 to 2028/29. This sets out that all National Health Service providers must meet the site-specific timeframes of the Government’s 150-day clinical trial set-up target. To support embedding research as part of everyday care, research activity and income should be reported to boards on a six-monthly basis.
We are embedding genomics as routine practice within the NHS and its workforce by delivering the genomics medicines service, seven NHS Genomic Laboratory Hubs and implementing whole genome sequencing as part of routine care. The Genomics Education Programme is responsible for upskilling the entire multi-professional, multi-specialty NHS workforce in genomics.
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on brain cancer to take place in England, by ensuring the patient population can be more easily contacted by researchers.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of guidance provided to patients on their (a) rights and (b) options for the (i) storage and (ii) future research use of their tissue samples.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department recognises the importance of ensuring that patients are fully informed about their rights, options, and choices regarding the storage and future research use of their tissue samples. The Human Tissue Authority (HTA) Code of Practice and Standards on Research aims to provide anyone undertaking activities relevant to this sector with a reference source which gives practical advice on the minimum steps necessary to comply with the relevant legislation and HTA policy. The code was updated in February 2025.
The HTA licenses and inspects organisations that collect human tissue. Their role is to make sure that organisations remove, store, and use brains, bodies, and tissues in an appropriate, respectful, and well-managed way, and that the wishes of individual patients and their families are respected. The HTA licensing standards establish consent as the fundamental legal and ethical requirements for the removal, storage, and use of human tissue.
The HTA’s regulatory framework helps ensure that tissue is stored to high standards, to be of most use to healthcare training and research.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to deliver (a) workforce and (b) training requirements to support an expansion of fresh-freezing facilities for brain cancer tissue in the NHS.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
There are currently no plans by the Department to expand fresh-freezing facilities for brain cancer tissue. Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
In the new year the Department will publish the National Cancer Plan. The plan will have patients at its heart and will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care, as well as research and innovation. The plan will seek to improve every aspect of cancer care to better the experiences and outcomes for all patient groups, including those with brain cancer.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress has been made by the (a) Medicines and Healthcare Products Regulatory Agency and (b) the Commission on Human Medicines to (i) understand the (A) current and (B) historic risks of sodium valproate when taken during pregnancy, and (ii) in communicating these risks to (1) healthcare professionals and (2) patients.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA), taking advice from the Commission on Human Medicines (CHM), has worked to raise awareness among healthcare professionals and patients of the risks of valproate when taken during pregnancy through several updates to the valproate Summary of Product Characteristics, for healthcare professionals, and the Patient Information Leaflets, as well as updates to associated educational materials as required.
The magnitude and type of risks associated with valproate use in pregnancy have been communicated in articles in the MHRA bulletin, Drug Safety Update, and via letters cascaded out through the NHS Central Alerting System. These communications have been supported by messages from the relevant professional bodies and regulatory requirements reinforced through changes to clinical guidelines and improved alerts on general practitioner prescribing systems.
The valproate Pregnancy Prevention Programme, implemented in 2018, is supported by educational materials for healthcare professionals and patients which describe the neurodevelopmental disorders and major congenital malformations associated with the use of valproate in pregnancy, and are available electronically and sent in hard copy format to healthcare professionals.
In January 2024, the MHRA communicated, in an article in a Drug Safety Update, the latest advice from the CHM, that valproate must not be started in new patients, male or female, younger than 55 years old unless two specialists independently consider and document that there is no other effective or tolerated treatment, or if there are compelling reasons that the reproductive risks do not apply. It was advised that women and girls of childbearing potential who are already receiving valproate should have their treatment reviewed by two specialists at their next annual review. The requirement for two specialists to review these patients is a one off, and subsequent annual reviews required under the Pregnancy Prevention Programme are undertaken by a single specialist.
Updated educational materials were made available to healthcare professionals and patients electronically, and sent to healthcare professionals in hard copy format, that could be provided to patients and which could support the discussions between healthcare professionals and patients.